ADSL identified as a therapeutic target in endocrine therapy-resistant ER+ breast cancer
April 18, 2023
Estrogen receptor (ER)-positive breast cancer is among the most prevalent subtypes and is the cause of most of the mortality among breast cancer patients. Endocrine therapy is effective in these cases, but the development of resistance is a fact in many cases.